专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110065141A1 Method of Diagnosing Pancreatic Cancer with the Use of N-Binding Type Sugar Chains 失效
标题翻译：使用N-结合型糖链诊断胰腺癌的方法
公开(公告)号：US20110065141A1
公开(公告)日：2011-03-17
申请号：US12991340
申请日：2009-05-08
申请人： Tokuzo Arao , Kazuko Matsumoto , Kazuto Nishio , Hiroki Sakamoto , Masayuki Kitano , Masatoshi Kudo
发明人： Tokuzo Arao , Kazuko Matsumoto , Kazuto Nishio , Hiroki Sakamoto , Masayuki Kitano , Masatoshi Kudo
IPC分类号： C12Q1/37 , C12Q1/34
CPC分类号： G01N33/57438 , Y10T436/24
摘要： The present invention is to provide a novel marker for diagnosing pancreatic cancer, a method for determining if a subject has pancreatic cancer utilizing the marker, etc. The present inventors collected blood from patients of 78 cases in total including patients of 24 cases with pancreaticobiliary-duct benign disorder (16 gallstone cases and 8 pancreatitis cases) and patients of 54 cases with pancreatic cancer, and mass spectrometry was performed on N-linked sugar chains in plasma. From the 74 mass-spectrometric peaks detected, 65 sugar chains were extracted based on the results of PAM analysis. These extracted sugar chains were then used to predict pancreatic cancer or pancreaticobiliary-duct benign disorder, to correctly diagnose 74% cases. Further, a T-test was performed between the two groups, the group of pancreaticobiliary-duct benign disorder and the group of pancreatic cancer, which identified two sugar chains, the sugar chain of m/z 3031 and the sugar chain of m/z 2362, as sugar chains demonstrating significant difference (p
摘要翻译：本发明提供一种用于诊断胰腺癌的新型标记物，用于确定受试者是否使用标记物的胰腺癌的方法等。本发明人从78例患者中收集了总共包括24例胰腺胆管癌患者的血液，膀胱良性疾病（16例胆囊病例和8例胰腺炎病例）和54例胰腺癌患者，并对血浆中的N链糖链进行质谱分析。根据PAM分析结果，从检测到的74个质谱峰中提取出65个糖链。然后将这些提取的糖链用于预测胰腺癌或胰胆管良性疾病，以正确诊断74％的病例。此外，在两组之间进行T检验，即胰胆管良性病变组和胰腺癌组，鉴定了两条糖链，m / z 3031的糖链和m / z的糖链 2362，由于糖链显示出显着性差异（p <0.05），并且两组之间的表达水平呈现2倍或更大的差异。使用这些糖链的正确检测率用六个分类器计算，所有这些分类器都得到约70％的正确检测结果。

2. 发明授权

US08372647B2 Method of diagnosing pancreatic cancer with the use of N-binding type sugar chains 失效
标题翻译：使用N-结合型糖链诊断胰腺癌的方法
公开(公告)号：US08372647B2
公开(公告)日：2013-02-12
申请号：US12991340
申请日：2009-05-08
申请人： Tokuzo Arao , Kazuko Matsumoto , Kazuto Nishio , Hiroki Sakamoto , Masayuki Kitano , Masatoshi Kudo
发明人： Tokuzo Arao , Kazuko Matsumoto , Kazuto Nishio , Hiroki Sakamoto , Masayuki Kitano , Masatoshi Kudo
IPC分类号： G01N33/48 , G01N24/00 , C12Q1/34 , C12Q1/37
CPC分类号： G01N33/57438 , Y10T436/24
摘要： The present invention provides novel markers for diagnosing pancreatic cancer, and methods for determining if a subject has pancreatic cancer utilizing the markers, etc. The methods involve comparing mass-spectrometric peaks of certain sugar chains, obtained from patients' blood and determining if there is a significant decrease in peak intensity, compared with corresponding peaks from patients without pancreatic cancer.
摘要翻译：本发明提供了用于诊断胰腺癌的新型标志物，以及用于确定受试者是否使用标记物具有胰腺癌的方法等。该方法包括比较从患者血液获得的某些糖链的质谱峰，并确定是否存在与没有胰腺癌患者的相应峰值相比，峰值强度显着降低。

3. 发明授权

US08802384B2 Method or system using biomarkers for the monitoring of a treatment 有权
标题翻译：用于监测治疗的生物标志物的方法或系统
公开(公告)号：US08802384B2
公开(公告)日：2014-08-12
申请号：US12720663
申请日：2010-03-09
申请人： Tokuzo Arao , Kanae Kudo , Kazuhiko Nakagawa , Kazuto Nishio
发明人： Tokuzo Arao , Kanae Kudo , Kazuhiko Nakagawa , Kazuto Nishio
IPC分类号： G01N33/53 , G01N33/574
CPC分类号： G01N33/5064 , G01N2800/52 , G01N2800/56
摘要： The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy.
摘要翻译：本发明涉及用于监测化合物3-Z- [1-（4-（N - （（4-甲基 - 哌嗪-1-基） - 甲基羰基）-N-甲基 - 氨基） - 苯胺的活性的生物标志物）-1-苯基 - 亚甲基] -6-甲氧基羰基-2-二氢吲哚酮或其药学上可接受的盐，特别是其单乙磺酸盐形式，当单独使用或任选与其它药学活性成分和/或其它处理如例如放射治疗。

4. 发明申请

US20130314526A1 CELL ANALYSIS DEVICE 审中-公开
标题翻译：细胞分析装置
公开(公告)号：US20130314526A1
公开(公告)日：2013-11-28
申请号：US13882257
申请日：2011-09-16
申请人： Kenji Yasuda , Hideyuki Terazono , Hyonchol Kim , Masahito Hayashi , Akihiro Hattori , Kazuto Nishio , Tokuzo Arao , Yohei Miyagi , Takashi Ohtsu
发明人： Kenji Yasuda , Hideyuki Terazono , Hyonchol Kim , Masahito Hayashi , Akihiro Hattori , Kazuto Nishio , Tokuzo Arao , Yohei Miyagi , Takashi Ohtsu
IPC分类号： G06T7/00
CPC分类号： G06T7/0016 , G01N15/1475 , G01N15/1484 , G01N27/447 , G01N33/487 , G01N2015/1006 , G01N2015/1472 , G01N2015/149 , G01N2015/1493 , G01N2015/1497
摘要： Provided is a cell concentration/purification device having a function of successively locating cells in a specific area of a microchannel, and a function of sequentially capturing cell images by use of light from a plurality of monochromatic light sources on an image basis, and performing comparative analysis of the cell images to recognize individual cells based on information on the shape of the cells and an absorption spectral distribution of the cells or inside of the cells, thereby selectively separating/purifying the cells.
摘要翻译：本发明提供一种细胞浓度/净化装置，其具有将细胞连续定位在微通道的特定区域中的功能，以及通过使用来自多个单色光源的光以图像为基础顺序捕获细胞图像的功能，并进行比较基于关于细胞形状的信息和细胞的吸收光谱分布或细胞内部的信息来分析细胞图像以识别个体细胞，从而选择性地分离/纯化细胞。

5. 发明申请

US20110237807A1 ROTAXANE COMPOUND AND ANTITUMOR AGENT 有权
标题翻译： ROTAXANE化合物和抗菌剂
公开(公告)号：US20110237807A1
公开(公告)日：2011-09-29
申请号：US13125394
申请日：2009-10-21
申请人： Toshikazu Takata , Yasuhito Koyama , Kazuko Nakazono , Toshihide Hasegawa , Young-Gi Lee , Nobufumi Ono , Kazuto Nishio , Yoshihiko Fujita
发明人： Toshikazu Takata , Yasuhito Koyama , Kazuko Nakazono , Toshihide Hasegawa , Young-Gi Lee , Nobufumi Ono , Kazuto Nishio , Yoshihiko Fujita
IPC分类号： C07D323/00
CPC分类号： C07D323/00 , A61K31/357
摘要： An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure. (In chemical formula 1, m≧2, n≧3, and X represents an anionic molecule or an anionic atom
摘要翻译：一种抗肿瘤剂，不容易从肿瘤细胞中排出，适用于局部治疗。具体公开的是含有以化学式1表示的化合物作为基础结构的轮烷化合物。（化学式1中，m≥2，n≥3，X表示阴离子性分子或阴离子性原子

6. 发明申请

US20130085081A1 RISK PREDICTION OF DEVELOPING DRUG-INDUCED LUNG INJURY AND DETECTION METHOD AND KIT OF GENE FOR RISK PREDICTION 审中-公开
标题翻译：开发药物诱发性肺损伤的风险预测及风险预测基因检测方法及工具包
公开(公告)号：US20130085081A1
公开(公告)日：2013-04-04
申请号：US13702574
申请日：2011-06-08
申请人： Fumiaki Koizumi , Shintaro Kanda , Tomohide Tamura , Koichi Goto , Masaru Sekijima , Akira Ohide , Kazuto Nishio
发明人： Fumiaki Koizumi , Shintaro Kanda , Tomohide Tamura , Koichi Goto , Masaru Sekijima , Akira Ohide , Kazuto Nishio
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6813 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N2800/122
摘要： Disclosed are a method of detecting the presence or absence of a single nucleotide polymorphism of a gene, for prediction of the risk of developing drug-induced lung injury, or for improving a therapeutic method, and a kit for carrying out the detection method. The detection method is characterized by comparing an ABCB1 gene in a biological sample with a wild-type ABCB1 gene to detect the presence or absence of a single nucleotide polymorphism in the ABCB1 gene in the biological sample, in particular, by determining the nucleotide at position 3751 of the CDS of the ABCB1 gene. The kit comprises an oligonucleotide probe which specifically binds to a single nucleotide polymorphism in an ABCB1 gene under selective binding conditions, or an oligonucleotide primer which amplifies a nucleic acid sequence comprising a single nucleotide polymorphism in an ABCB1 gene.
摘要翻译：公开了检测基因的单核苷酸多态性的存在或不存在，用于预测发生药物诱导的肺损伤的风险或用于改善治疗方法的方法以及用于进行检测方法的试剂盒。检测方法的特征在于将生物样品中的ABCB1基因与野生型ABCB1基因进行比较，以检测生物样品中ABCB1基因中单核苷酸多态性的存在或不存在，特别是通过确定位置上的核苷酸 375B的ABCB1基因的CDS。该试剂盒包含在选择性结合条件下特异性结合ABCB1基因的单核苷酸多态性的寡核苷酸探针，或扩增ABCB1基因中包含单核苷酸多态性的核酸序列的寡核苷酸引物。

7. 发明授权

US08207357B2 Rotaxane compound and antitumor agent 有权
标题翻译： Rotaxane化合物和抗肿瘤剂
公开(公告)号：US08207357B2
公开(公告)日：2012-06-26
申请号：US13125394
申请日：2009-10-21
申请人： Toshikazu Takata , Yasuhito Koyama , Kazuko Nakazono , Toshihide Hasegawa , Young-Gi Lee , Nobufumi Ono , Kazuto Nishio , Yoshihiko Fujita
发明人： Toshikazu Takata , Yasuhito Koyama , Kazuko Nakazono , Toshihide Hasegawa , Young-Gi Lee , Nobufumi Ono , Kazuto Nishio , Yoshihiko Fujita
IPC分类号： C07D323/00
CPC分类号： C07D323/00 , A61K31/357
摘要： An antitumor agent which is not easily excreted from tumor cells and is suitable for a topical treatment. Specifically disclosed is a rotaxane compound with contains a compound represented by chemical formula 1 as the base structure. (In chemical formula 1, m≧2, n≧3, and X represents an anionic molecule or an anionic atom.
摘要翻译：一种抗肿瘤剂，不容易从肿瘤细胞中排出，适用于局部治疗。具体公开的是含有以化学式1表示的化合物作为基础结构的轮烷化合物。（化学式1中，m≥2，n≥3，X表示阴离子性分子或阴离子性原子。

8. 发明申请

US20080286785A1 Method to predict or monitor the response of a patient to an erbb receptor drug 审中-公开
标题翻译：预测或监测患者对erbb受体药物反应的方法
公开(公告)号：US20080286785A1
公开(公告)日：2008-11-20
申请号：US12080959
申请日：2008-04-07
申请人： Kazuto Nishio , Hideharu Kimura , Kazuo Kasahara
发明人： Kazuto Nishio , Hideharu Kimura , Kazuo Kasahara
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor.
摘要翻译：本发明提供了一种检测ErbB受体突变的方法，其包括从患者提供生物流体样品的步骤; 从所述样品中提取DNA; 并筛选出所述DNA存在一种或多种改变受体中酪氨酸激酶活性的突变。

9. 发明授权

US06683083B1 Anticancer agents 失效
标题翻译：抗癌剂
公开(公告)号：US06683083B1
公开(公告)日：2004-01-27
申请号：US10089718
申请日：2002-08-02
申请人： Noboru Kaneko , Kazuto Nishio
发明人： Noboru Kaneko , Kazuto Nishio
IPC分类号： A61K31496
CPC分类号： A61K31/496
摘要： Disclosed herein is a method for suppressing the growth of cancer cells in a mammal in need of such treatment comprising administering to said mammal a cancer cell suppressing amount of a diphenylmethylpiperazine represented by the following general formula [1]: wherein R represents: or a pharmaceutically acceptable salt thereof. Compared with conventional anticancer agents, these agents are less toxic and exert an excellent carcinostatic effect on various solid cancers. Moreover, these anticancer agents inhibit the proliferation of fibroblasts, which makes them efficacious against pulmonary fibrosis and proliferative keloid lesions.
摘要翻译：本文公开了抑制需要这种治疗的哺乳动物中癌细胞生长的方法，包括向所述哺乳动物施用抑制量的由以下通式[1]表示的二苯基甲基哌嗪：其中R表示：或药学上与常规抗癌剂相比，这些药物毒性较小，对各种固体癌症具有优异的制癌作用。此外，这些抗癌剂抑制成纤维细胞的增殖，这使得它们对肺纤维化和增生性瘢痕疙瘩病变有效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式